Table 4.
ESBL producing E. coli and K. pneumoniae susceptibility rates from Gram-negative IAI & UTI isolates obtained from ICU and non-ICU units
| IPM | ETP | AMK | TZP | FOX | CAZ | CRO | CTX | FEP | LVX | CIP | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| IAI-E. coli ESBL +(n=538) | ||||||||||||
| ICU (n=97) | 95.88 | 85.57 | 91.75 | 77.32 | 56.7 | 34.02 | 0 | 0 | 4.12 | 24.74 | 25.77 | |
| Non-ICU (n=441) | 97.50 | 91.84 | 94.33 | 83.45 | 58.05 | 31.52 | 0 | 0 | 3.17 | 29.25 | 27.21 | |
| P-value | 0.326 | 0.079 | 0.350 | 0.185 | 0.821 | 0.632 | 0.547 | 0.456 | 0.900 | |||
| IAI-K. pneumoniae ESBL +(n=122) | ||||||||||||
| ICU (n=20) | 80.00 | 70.00 | 90.00 | 55.00 | 65.00 | 15.00 | 0.00 | 0.00 | 5.00 | 35.00 | 30.00 | |
| Non-ICU (n=102) | 83.33 | 78.43 | 83.33 | 57.84 | 49.02 | 25.49 | 0.00 | 0.00 | 2.94 | 38.24 | 35.29 | |
| P-value | 0.748 | 0.398 | 0.736 | 0.810 | 0.227 | 0.399 | 0.516 | 1.000 | 0.799 | |||
| UTI-E. coli ESBL +(n=556) | ||||||||||||
| ICU (n=39) | 94.87 | 92.31 | 92.31 | 87.18 | 64.1 | 38.46 | 0.00 | 0.00 | 0.00 | 28.21 | 25.64 | |
| Non-ICU (n=517) | 97.18 | 91.34 | 94.92 | 89.10 | 62.22 | 37.10 | 1.69 | 1.13 | 4.14 | 24.86 | 22.74 | |
| P-value | 0.339 | 1.000 | 0.447 | 0.603 | 0.733 | 0.865 | 1.000 | 1.000 | 1.000 | 0.702 | 0.694 | |
| UTI-K. pneumoniae ESBL +(n=109) | ||||||||||||
| ICU (n=13) | 85.71 | 85.71 | 78.57 | 57.14 | 50.00 | 7.14 | 0.00 | 0.00 | 0.00 | 28.57 | 28.57 | |
| Non-ICU (n=96) | 87.76 | 81.63 | 89.8 | 62.24 | 62.24 | 26.53 | 2.04 | 3.06 | 3.06 | 34.69 | 30.61 | |
| P-value | 0.673 | 1.000 | 0.186 | 0.558 | 0.365 | 0.184 | 1.000 | 1.000 | 1.000 | 1.000 | 1.000 |
Abbreviations: ICU, intensive care unit; IAI, intraabdominalinfection; UTI, urinary tract infection; IPM, Carbapenems: Imipenem; ETP, Ertapenem; AMK, Aminoglycoside: Amikacin; TZP, Piperacillin-Tazobactam; FOX, Cephalosporins: Cefoxitin, CAZ, Ceftazidime, CRO, Ceftriaxone, CTX, Cefotaxime, FEP, Cefepime; LVX, Fluoroquinolones: Levofloxacin; CIP, Ciprofloxacin.